Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3BN4W)

Drug Name
CFI-400945 Drug Info
Synonyms CFI 400945; CFI400945
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [1]
Cross-matching ID
PubChem CID
58486178
CAS Number
CAS 1338806-73-7
TTD Drug ID
DM3BN4W

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Polo-like kinase 4 (PLK4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
XMD8-92 DMZIHKY Discovery agent N.A. Investigative [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Polo-like kinase 4 (PLK4) TTGPNZQ PLK4_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04176848) CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer. U.S. National Institutes of Health.
2 Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014 Aug 11;26(2):163-76.
3 Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 2010 Sep 14;18(3):258-67.